Boxer Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Boxer Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-250,000	Closed	-$20.9M	–	92
2021 Q2	$20.9M	Hold	250,000	–	–	0.74%	40
2021 Q1	$18.9M	Hold	250,000	–	–	0.64%	45
2020 Q4	$21.9M	Hold	250,000	–	–	0.7%	40
2020 Q3	$19M	Hold	250,000	–	–	0.66%	38
2020 Q2	$30.8M	Hold	250,000	–	–	1.36%	28
2020 Q1	$21.1M	Hold	250,000	–	–	1.44%	22
2019 Q4	$21.1M	Sell	250,000 -200,000	-44%	-$15.1M	1.2%	24
2019 Q3	$30.3M	Buy	+450,000	New	+$34.7M	2.2%	17
2016 Q4	–	Sell	-100,000	Closed	-$9.25M	–	29
2016 Q3	$9.25M	Buy	100,000 +30,000	+43%	+$2.82M	4.15%	10
2016 Q2	$5.45M	Hold	70,000	–	–	4.83%	10
2016 Q1	$5.77M	Buy	+70,000	New	+$5.7M	5.65%	8

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Boxer Capital's BMRN Position: Q3 2021 in Review

Boxer Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 250,000 shares — an estimated $20.9M sold.

Boxer Capital first reported a position in BMRN in Q1 2016 and held it in 11 quarters. The position peaked at $30.8M in Q2 2020. 512 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Boxer Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Boxer Capital sold 250,000 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $20.9M.
Boxer Capital first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 11 quarters.
Boxer Capital's BioMarin Pharmaceuticals position peaked at $30.8M in Q2 2020.
512 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Boxer Capital's 13F filing for Q3 2021, filed 15 Nov 2021.